Background: Therapeutic vancomycin trough levels correlate with therapeutic success and the development of renal failure. In this study, we aimed to describe the safety and outcome of pharmacy-led vancomycin dosing and monitoring. Methods: We included adults requiring vancomycin for >48 h and who had a vancomycin trough level drawn near steady state. The primary outcome of the comparison was the achievement of therapeutic trough levels, defined as 10-20 µg/ml. Secondary outcome included acute renal failure. We compared these outcomes before and after the implementation of pharmacy-led vancomycin dosing and monitoring. Result: During the study period, a total of 278 patients were in the preimplementation phase and 286 were in the postintervention phase. There was a clear increase in the percentage of patients achieving the therapeutic range (50.5 vs. 79.7%, p = 0.0001) and an increase in the percentage of levels within the therapeutic range (31.6 vs. 59.1%; p = 0.0001). The number of cases receiving vancomycin increased by 5% and the duration of therapy decreased by 19.5%. More patients attained a therapeutic range of 10-20 µg/ml (i.e. the level was 31.6% in the preintervention and 59.1% in the postintervention phase). Conclusions: A higher percentage of patients achieved a therapeutic range and less nephrotoxicity when using a pharmacy-led protocol for vancomycin dosing.

Keywords:
Vancomycin, Therapeutic drug monitoring, Toxicity
1.
Moellering RC Jr: Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42(suppl 1):S3-S4.
2.
Ryback M, Lomaestro B, Rotchafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health System Pharmacists, the Infectious Disease Society of America and Society of Infectious Disease Pharmacists. Am J Health Syst Pharm 2009;1:82-98.
3.
Ye Z-K, Tang H-L, Zhai S-D: Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One 2013;8:e77169.
4.
Frymoyer A, Guglielmo BJ, Hersh AL: Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J 2013;32:1077-1079.
5.
Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A: Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68:1243-1255.
6.
Swartling M, Gupta R, Duas V, et al: Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm 2012;34:282-285.
7.
Carroll DJ, Austin GE, Stajich GV, et al: Effect of education on the appropriateness of serum drug concentration determination. Ther Drug Monit 1992;14:81-84.
8.
Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ: Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. Pharmacotherapy 2013;33:1256-1263.
9.
Brunetti L: Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a community medical center. Poster Abstract Session: Stewardship: Implementing Programs, ID week, San Francisco, October 2013.
10.
Luxenburg J: Hitting the target: outcomes of a pharmacy-managed vancomycin dosing and monitoring strategy at a tertiary-care VA medical center. Poster Abstract Session: Antibiotic Stewardship: Theory and Practice, ID week, San Diego, October 2012.
11.
Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-1336.
12.
Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, Sakurai K, Miyamoto A: Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. Chemotherapy 2013;59:319-324.
13.
Contreiras C, Legal M, Lau TT, Thalakada R, Shalansky S, Ensom MH: Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. Can J Hosp Pharm 2014;67:126-132.
14.
Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, Takeyama M, Kadota J: Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 2012;58:308-312.
15.
Hall AB, Montero J, Cobian J, Regan T: The effects of an electronic order set on vancomycin dosing in the ED. Am J Emerg Med 2015;33:92-94.
16.
Wesner AR, Brackbill ML, Coyle LL, Kidd RS: Prospective trial of a novel nomogram to achieve updated vancomycin trough concentrations. Interdiscip Perspect Infect Dis 2013;2013:839456.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.